1. Fas ligand expression in BRCA1-associated hereditary breast carcinoma clearly differs from that in sporadic breast carcinoma

   • Yasuhiro Ito
   • Shinzaburo Noguchi
   • Nariaki Matsuura

   OriginalPaper Pages: 95 - 100

2. Metastatic bone pain palliation with 89‐Sr and 186‐Re‐HEDP in breast cancer patients

   • Rosa Sciuto
   • Anna Festa
   • Carlo L. Maini

   OriginalPaper Pages: 101 - 109

3. Oncostatin M–induced growth inhibition and morphological changes of MDA‐MB231 breast cancer cells are abolished by blocking the MEK/ERK signaling pathway

   • Cong Li
   • Thomas E. Ahlborn
   • Jingwen Liu

   OriginalPaper Pages: 111 - 121

4. Are medical oncologists biased in their treatment of the large woman with breast cancer?

   • Yolanda Madarnas
   • Carol A. Sawka
   • Georg A. Bjarnason

   OriginalPaper Pages: 123 - 133

5. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women

   • Patrizia Querzoli
   • Giuseppe Albonico
   • Italo Nenci

   OriginalPaper Pages: 135 - 142

6. Generation of reactive oxygen species by xanthine derivatives in MDA‐MB‐231 human breast cancer cells

   • T.L. Crumpton
   • F.J. Seidler
   • T.A. Slotkin

   OriginalPaper Pages: 143 - 146

7. Methyl‐substituted diindolylmethanes as inhibitors of estrogen‐induced growth of T47D cells and mammary tumors in rats

   • Andrew McDougal
   • Mona Sethi Gupta
   • Stephen H. Safe

   OriginalPaper Pages: 147 - 157

8. Clinical significance of vascular endothelial growth factor‐C (VEGF‐C) in breast cancer

   • Junko Kinoshita
   • Kaoru Kitamura
   • Keizo Sugimachi

   OriginalPaper Pages: 159 - 164

9. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors

   • Kazuyuki Yazawa
   • Minoru Fujimori
   • Shun’ichiro Taniguchi

   OriginalPaper Pages: 165 - 170

10. Second primary breast cancer in men

    • Chuanhui Dong
    • Kari Hemminki

    OriginalPaper Pages: 171 - 172